GOOD
BUSINESS
DELHI-NCR
Biocon gets USFDA nod for breast cancer drug
New Delhi: Biopharmaceutical company Biocon Ltd on Monday said it has received approval from the US Food and Drug Administration (FDA) for Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta, used in the treatment of HER2-positive
Read the original at Economic Times ↗